Editorial: in the era of effective antiviral therapy, long-term dynamic endoscopic monitoring does not seem to be necessary for all CHB patients with compensated cirrhosis

Affiliations

Editorial

Lan-Qing Li et al. Aliment Pharmacol Ther. 2023 Jun.

. 2023 Jun;57(12):1467-1468.

doi: 10.1111/apt.17487.

¹ Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.

No abstract available

Comment on

Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
Farina E, Loglio A, Tosetti G, Degasperi E, Viganò M, Gentile C, Monico S, Perbellini R, Borghi M, Facchetti F, Uceda Renteria SC, Ceriotti F, Cerini F, Primignani M, Lampertico P. Farina E, et al. Aliment Pharmacol Ther. 2023 Jun;57(12):1407-1416. doi: 10.1111/apt.17463. Epub 2023 Mar 28. Aliment Pharmacol Ther. 2023. PMID: 36978230

1. Nett A, Binmoeller KF. Endoscopic management of portal hypertension-related bleeding. Gastrointest Endosc Clin N Am. 2019;29:321-37.
1. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-52.
1. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725-49.
1. Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol. 2013;19:6849-56.
1. Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology. 2019;156:997-1009 e1005.